Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACI-7104.056 in Early Parkinson's Disease
NCT06015841Phase 2Active, not recruiting
- Sponsor
- AC Immune SA
- Start
- Jul 2023
- Primary completion
- Jun 2028
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of AFFITOPE PD01A in Parkinson's disease (PD) (4 arms), sponsored by AC Immune SA. Primary endpoints: Number of participants with Adverse Events, Number of participants with abnormal MRI results and 3 more. Started Jul 2023; status: active, not recruiting.
02
Drugs
AFFITOPE PD01A
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06015841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015841.